Here are the 8-K filings from ADARx Pharmaceuticals, Inc. (ADRX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow ADRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ADRX filings page.
ADARx Pharmaceuticals, Inc. closed its initial public offering on September 28, 2026, selling 26,250,000 shares of common stock at $17.00 per share. Gross IPO proceeds were approximately $446.3 million before underwriting discounts and commissions and estimated offering expenses payable by the company.
At the same closing, AbbVie Inc. purchased 5,255,542 shares in a private placement at the IPO price, generating approximately $89.3 million in gross proceeds before placement-agent fees and estimated private-placement expenses payable by ADARx. The purchase agreement set the share amount to result in AbbVie owning approximately 4.9% of common stock following the IPO and private placement, and capped its purchase at $100.0 million. ADARx paid a placement-agent fee equal to 2.0% of the total purchase price. The amended and restated certificate of incorporation and bylaws took effect in connection with the IPO closing; both had previously been approved by the board and stockholders. Ryan Fisk, the Chief Financial Officer and Chief Business Officer, signed the report.